We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Clinical ddPCR Diagnostic Test System Gets FDA Clearance

By LabMedica International staff writers
Posted on 07 Mar 2019
A test designed for monitoring treatment response in chronic myeloid leukemia and is also the first-ever digital polymerase chain reaction (PCR) product to receive US official government approval.

The test uses a clinical instrument, called the QXDx AutoDG Droplet Digital ddPCR System. More...
It is designed to give users the flexibility to run US Food and Drug Administration (FDA, Silver Springs, MD, USA) -cleared in vitro diagnostic medical device (IVD) tests, as well as laboratory developed tests, and uses a simple, user-friendly workflow that is also scalable.

The QXDx BCR-ABL %IS Kit was CE marked in late 2017. The test uses Bio-Rad's clinical instrument, called the QXDx AutoDG ddPCR System. It quantifies BCR-ABL fusions, specifically p210 transcripts, and can detect the residual levels seen in patients on tyrosine kinase inhibitor therapy. Measuring residual levels of BCR-ABL in chronic myeloid leukemia (CML) patients treated with the first-line tyrosine kinase inhibitor (TKI) imatinib, for example, can help physicians decide whether it might be necessary to start a second-line TKI, such as dasatinib, nilotinib, or bosutinib.

Digital PCR-based methods can offer lower levels of resolution than standard quantitative reverse transcription PCR (RT-qPCR). Bio-Rad's new test can detect molecular response down to MR 4.7 (LOD), or 0.002% on an International Scale, according to the firm's website, with levels of BCR-ABL between 0.01% and 0.001% defining a so-called deep molecular response that predicts better long-term outcomes.

Bio-Rad introduced ddPCR as a research tool in 2012, and it was quickly adopted for liquid biopsy and rare mutation detection in cancer research, the firm noted in a statement. To date, there are more than 3,400 publications citing the ddPCR technology, including more than 900 publications focused on liquid biopsy.

Related Links:
US Food and Drug Administration


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.